The document discusses documentation and standard operating procedures (SOPs) for GMP compliance. It describes issues found at a pharmaceutical company (Goran Pharma) regarding inadequate testing of glycerin lots for impurities. The FDA found the company's responses to be inadequate. The document also discusses how to properly write SOPs, including getting appropriate reviews and authorization. It provides examples of documentation issues found during an FDA inspection at another company (Lupin) regarding inadequate cleaning processes and validation. The FDA requested extensive corrective and preventative actions from Lupin to address their cleaning validation program and ensure proper documentation and process controls.